Navigation Links
Integrated Biopharma's Proprietary Vaccine Technology Achieves,Strong Positive Results

HILLSIDE, N.J., March 12, 2007 /PRNewswire-FirstCall/ -- InB:Biotechnologies, Inc. ("BioTech"), a wholly-owned subsidiary of Integrated BioPharma, Inc. , today announced strong positive results in studies of vaccines against HPV, anthrax and plague made using INBP's novel, proprietary AIPwLV(TM) vaccine technology. The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the Contract Research Organization led by Dr. Vidadi Yusibov, through which BioTech executes its vaccine-related development activities.

The results, reported in the respected peer-reviewed scientific journal Vaccine, demonstrated pre-clinical efficacy of key HPV proteins produced by the AIPwLV(TM) technology, which induced specific immune responses and protected against HPV challenge infection. HPV is the primary etiologic agent of cervical cancer, which represents the third leading cause of cancer-related death among women worldwide. The reported results support the possibility of producing prophylactic and therapeutic HPV vaccines using the AIPwLV(TM) technology.

The studies also demonstrated that other vaccine candidates made using the AIPwLV(TM) technology induced specific immune responses and conferred complete protection against lethal doses of anthrax and plague, two substances considered as likely bioterrorism agents.

"The AIPwLV(TM) technology achieves rapid, high level production of antigens, antibodies and therapeutic proteins in non-genetically modified plants utilizing a proprietary launch-vector technology," said Dr. Yusibov, the Executive Director of CMB. "It offers rapid, unparalleled scalability of vaccine production and cost efficiency, addressing the principal concerns affecting current methods of vaccine production, particularly where large scale or rapid inoculation is desired," added Dr. Yusibov.

About Integrated BioPharma, Inc.

Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.

Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.

CONTACT: Jeffery Leach, VP, or Dina Masi, CFO, , bothof Integrated BioPharma Inc., +1-888-319-6962 d.masi@ibiopharma.com

Web site: http://www.iBioPharma.com/

Ticker Symbol: (NASDAQ-NMS:INBP)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
8. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
11. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):